榮昌生物-B(09995.HK)公開發售獲約53.43倍認購 上限定價52.10港元/股
格隆匯 11 月 6日丨榮昌生物-B(09995.HK)發佈公告，公司全球發售7653.7萬股股份，其中香港發售股份3061.5萬股，國際發售股份4592.2萬股，另有15%超額配股權；發售價已釐定為每股發售股份52.10港元，每手買賣單位500股；摩根士丹利、華泰國際及摩根大通為聯席保薦人，預期股份將於2020年11月9日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港發售股份獲非常大幅超額認購。香港公開發售合共接獲22,261份有效申請，認購合共約4.09億股香港發售股份，相當於根據香港公開發售初步可供認購的H股總數約53.43倍。根據國際發售初步提呈發售的H股已獲超額認購，相當於根據國際發售初步可供認購的H股總數約22倍。
基於每股發售股份發售價為52.10港元，根據相關基石投資協議，公司的基石投資者已認購合共3383.95萬股H股，合共相當於緊隨全球發售完成後公司已發行股本約7.07%及全球發售的發售股份數目約44.21%，在兩種情況下均假設超額配股權並無獲行使。
根據發售價每股H股52.10港元，公司自全球發售收取的所得款項淨額估計約為37.766億港元(假設超額配股權並無獲行使)。公司擬將所得款項淨額約15.0%用於撥付泰它西普(RC18)正在進行中以及計劃開展的臨牀試驗、註冊備案的準備事宜、上市及在取得監管批准的情況下進行商業化(包括銷售及營銷)；約15.0%將用於撥付disitamab vedotin (RC48)正在進行中以及計劃開展的臨牀試驗及潛在註冊備案准備；約5.0%將用於撥付RC28在中國治療濕性AMD、DME及DR的正在進行中以及計劃開展的臨牀試驗；約15.0%將用於撥付開發RC88及 RC98，以及早期藥物發現及開發；約25.0%將用於撥付建設新生產設施以擴大商業生產產能；約15.0%將用於償還榮昌製藥借款；及約10.0%將用作一般企業及營運資金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
